Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
19. Oktober 2022 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial...
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
12. Oktober 2022 08:30 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial...
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
09. Juni 2022 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel...
Innoviva to Acquire Entasis Therapeutics
23. Mai 2022 08:30 ET
|
Entasis Therapeutics Holdings Inc.; Innoviva, Inc.
Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cashPrice per share in cash represents a 50% premium to Entasis’ closing price of $1.47 per share...
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
17. Mai 2022 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
27. April 2022 07:30 ET
|
Entasis Therapeutics Holdings Inc.
Highlights of landmark Phase 3 ATTACK trial for sulbactam-durlobactam (SUL-DUR) presented at ECCMID 2022 annual conferenceSUL-DUR NDA submission on track for mid-2022Zoliflodacin Phase 3 trial...
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference
26. April 2022 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of...
Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference
18. April 2022 08:30 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of...
Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update
03. März 2022 07:30 ET
|
Entasis Therapeutics Holdings Inc.
Phase 3 ATTACK registrational trial for sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints, NDA submission planned for mid-2022Zoliflodacin Phase 3 trial progressing;...
Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.
02. Februar 2022 16:33 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...